Less than 20% of the monoclonal antibody doses shipped by two companies, Indianapolis-based Lilly and New York-based Regeneron, have have used, officials say, even though they can reduce hospitalizations by up to 70%.
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
With Mundo Sanchez’s help, the refrigerated-trucking company has grown 1,000% over the past five years and this year made IBJ’s Fast 25 list of fastest-growing central Indiana companies.
Cindy Lucchese steers the financial fortunes of Penske Entertainment, the Roger Penske-owned entity she helped create when the racing icon bought the Indianapolis Motor Speedway, the IndyCar series and IMS Productions from the Hulman family in January 2020.
With Todd Young’s guidance, Elanco spun off from Eli Lilly and Co. in March 2019. In the process, Young built a 60-person corporate finance department from scratch.
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
Elanco Animal Health Inc.’s announcement Friday that it will move its headquarters to Indianapolis came as a surprise to many business leaders in Greenfield. While disappointed, they say they are hopeful the move won’t be a significant blow to the city’s economy.
The total doesn’t include the value of the land the state will give to Elanco Animal Health for the project. Even so, the combined city and state package is possibly the largest amount of tax breaks ever considered for an economic development deal in Indiana.
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
During IBJ’s Engage Indiana 2020 virtual event Thursday morning, Eli Lilly & Co. CEO Dave Ricks said he always believed enhancing diversity and inclusion was important, but this year showed him how serious a problem racial injustice is and fueled his motivation to do more to address it.
While efforts to create a COVID-19 vaccine have garnered the most headlines, Eli Lilly and Co. turned its attention to another critical need—helping those who contract the disease get better.
